These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 23558051)

  • 1. Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy.
    Despierre E; Lambrechts S; Leunen K; Berteloot P; Neven P; Amant F; O'Shannessy DJ; Somers EB; Vergote I
    Gynecol Oncol; 2013 Jul; 130(1):192-9. PubMed ID: 23558051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folate Receptor Alpha Expression in Platinum Resistant/Refractory Ovarian Carcinomas and Primary Endocervical Adenocarcinomas.
    Rubinsak LA; Cohen C; Khanna N; Horowitz IR; Hanley KZ
    Appl Immunohistochem Mol Morphol; 2018 Sep; 26(8):567-572. PubMed ID: 27941566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of folate receptor-α (FRA) in gynecologic malignancies and its relationship to the tumor type.
    O'Shannessy DJ; Somers EB; Smale R; Fu YS
    Int J Gynecol Pathol; 2013 May; 32(3):258-68. PubMed ID: 23518909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of folate receptors alpha and beta in normal and cancerous gynecologic tissues: correlation of expression of the beta isoform with macrophage markers.
    O'Shannessy DJ; Somers EB; Wang LC; Wang H; Hsu R
    J Ovarian Res; 2015 May; 8():29. PubMed ID: 25971554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defective expression of Protein 4.1N is correlated to tumor progression, aggressive behaviors and chemotherapy resistance in epithelial ovarian cancer.
    Xi C; Ren C; Hu A; Lin J; Yao Q; Wang Y; Gao Z; An X; Liu C
    Gynecol Oncol; 2013 Dec; 131(3):764-71. PubMed ID: 23994105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum folate receptor alpha as a biomarker for ovarian cancer: Implications for diagnosis, prognosis and predicting its local tumor expression.
    Kurosaki A; Hasegawa K; Kato T; Abe K; Hanaoka T; Miyara A; O'Shannessy DJ; Somers EB; Yasuda M; Sekino T; Fujiwara K
    Int J Cancer; 2016 Apr; 138(8):1994-2002. PubMed ID: 26595060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fischer 344 Rat: A Preclinical Model for Epithelial Ovarian Cancer Folate-Targeted Therapy.
    Azaïs H; Queniat G; Bonner C; Kerdraon O; Tardivel M; Jetpisbayeva G; Frochot C; Betrouni N; Collinet P; Mordon S
    Int J Gynecol Cancer; 2015 Sep; 25(7):1194-200. PubMed ID: 26244757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the specificity of a new folate-targeted photosensitizer for peritoneal metastasis of epithelial ovarian cancer to enable intraperitoneal photodynamic therapy. A preclinical study.
    Azaïs H; Schmitt C; Tardivel M; Kerdraon O; Stallivieri A; Frochot C; Betrouni N; Collinet P; Mordon S
    Photodiagnosis Photodyn Ther; 2016 Mar; 13():130-138. PubMed ID: 26200606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy.
    Bellone S; Siegel ER; Cocco E; Cargnelutti M; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Int J Gynecol Cancer; 2009 Jul; 19(5):860-6. PubMed ID: 19574774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EphA8 is a prognostic marker for epithelial ovarian cancer.
    Liu X; Xu Y; Jin Q; Wang W; Zhang S; Wang X; Zhang Y; Xu X; Huang J
    Oncotarget; 2016 Apr; 7(15):20801-9. PubMed ID: 26989075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma.
    Xu N; Zhang Z; Zhu J; Xu L; Li Y; Duan L; Mao Y; Li H
    Int J Exp Pathol; 2016 Apr; 97(2):150-8. PubMed ID: 27127000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclin A correlates with YB1, progression and resistance to chemotherapy in human epithelial ovarian cancer.
    Cybulski M; Jarosz B; Nowakowski A; Jeleniewicz W; Kutarska E; Bednarek W; Stepulak A
    Anticancer Res; 2015 Mar; 35(3):1715-21. PubMed ID: 25750333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer.
    Crane LM; Arts HJ; van Oosten M; Low PS; van der Zee AG; van Dam GM; Bart J
    Cell Oncol (Dordr); 2012 Feb; 35(1):9-18. PubMed ID: 21647742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
    Ma Y; Li Y; Cui H; Liang XD; Tang ZJ; Li XP; Zhao Y; Wei LH
    Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Specific folic-acid targeted photosensitizer. The first step toward intraperitoneal photodynamic therapy for epithelial ovarian cancer].
    Azaïs H; Frochot C; Grabarz A; Khodja Bach S; Colombeau L; Delhem N; Mordon S; Collinet P
    Gynecol Obstet Fertil Senol; 2017 Apr; 45(4):190-196. PubMed ID: 28359805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Folate Receptor α Expression Level Correlates With Histologic Grade in Lung Adenocarcinoma.
    Driver BR; Barrios R; Ge Y; Haque A; Tacha D; Cagle PT
    Arch Pathol Lab Med; 2016 Jul; 140(7):682-5. PubMed ID: 26599808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical expression of VEGF predicts response to platinum based chemotherapy in patients with epithelial ovarian cancer.
    Siddiqui GK; Maclean AB; Elmasry K; Wong te Fong A; Morris RW; Rashid M; Begent RH; Boxer GM
    Angiogenesis; 2011 May; 14(2):155-61. PubMed ID: 21221762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes.
    Skaznik-Wikiel ME; Lesnock JL; McBee WC; Beriwal S; Zorn KK; Richard SD; Krivak TC; Edwards RP
    Int J Gynecol Cancer; 2012 Feb; 22(2):232-7. PubMed ID: 22080886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression.
    Deng J; Wang L; Chen H; Li L; Ma Y; Ni J; Li Y
    Cancer Metastasis Rev; 2013 Dec; 32(3-4):535-51. PubMed ID: 23609751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.